Technical Analysis for RAC - Race Oncology Ltd  

Grade Last Price % Change Price Change
B 1.370 -1.08% -0.015
RAC closed down 1.08 percent on Friday, April 19, 2024, on 63 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Strong but Oversold Other 0.00%
Outside Day Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -1.08%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.08%
NR7 Range Contraction -1.08%
Narrow Range Bar Range Contraction -1.08%
Stochastic Reached Oversold Weakness -1.08%
Strong but Oversold Other -1.08%

   Recent Intraday Alerts

Alert Time
Down 1% about 19 hours ago
Fell Below Previous Day's Low about 20 hours ago
Outside Day about 20 hours ago
Gap Up Closed about 20 hours ago
Reversed from Up about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Race Oncology Ltd   Description

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Cancer Drugs Clinical Medicine Cancers Therapy Oncology Chemotherapy Isan Leukemia

Is RAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.97
52 Week Low 0.64
Average Volume 157,822
200-Day Moving Average 1.008
50-Day Moving Average 1.169
20-Day Moving Average 1.474
10-Day Moving Average 1.499
Average True Range 0.098
RSI (14) 48.72
ADX 48.98
+DI 32.140
-DI 17.864
Chandelier Exit (Long, 3 ATRs) 1.447
Chandelier Exit (Short, 3 ATRs) 1.578
Upper Bollinger Bands 1.662
Lower Bollinger Band 1.286
Percent B (%b) 0.22
BandWidth 25.536
MACD Line 0.062
MACD Signal Line 0.105
MACD Histogram -0.0437
Fundamentals Value
Market Cap 175.58 Million
Num Shares 128 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -29.78
Price-to-Sales 0.00
Price-to-Book 48.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.490
Resistance 3 (R3) 1.503 1.477 1.470
Resistance 2 (R2) 1.477 1.446 1.470 1.463
Resistance 1 (R1) 1.423 1.427 1.410 1.410 1.457
Pivot Point 1.397 1.397 1.390 1.390 1.397
Support 1 (S1) 1.343 1.366 1.330 1.330 1.283
Support 2 (S2) 1.317 1.347 1.310 1.277
Support 3 (S3) 1.263 1.317 1.270
Support 4 (S4) 1.250